Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)
-
Wed, 23-Mar-2022
- Posted by: Biocon Biologics
No Comments
Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
-
Mon, 28-Feb-2022
- Posted by: Biocon Biologics
Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
-
Thu, 20-Jan-2022
- Posted by: Biocon Biologics
The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart
-
Fri, 07-Jan-2022
- Posted by: Biocon Biologics
Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
-
Thu, 30-Dec-2021
- Posted by: Biocon Biologics
Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
-
Thu, 23-Dec-2021
- Posted by: Biocon Biologics
Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
-
Wed, 01-Dec-2021
- Posted by: Biocon Biologics
Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
-
Fri, 19-Nov-2021
- Posted by: Biocon Biologics
Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
-
Tue, 16-Nov-2021
- Posted by: Biocon Biologics
Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day
-
Mon, 15-Nov-2021
- Posted by: Biocon Biologics
